We aim at creating a stable and quality driven research cluster in Biomedicine.

STRATEGY.

We believe multidisciplinary approach is the only way to provide added value and competitiveness in biomedical research.

We aim to coordinate multidisciplinary basic, clinical and epidemiological research at the University and Health Centers, from different perspectives and experiences. This will help the development of new drugs, the better understanding of diseases, or the design of novel diagnostic techniques, with a clear benefit applied to patients, the hospital, and social environment

With regard to cancer research, several groups are now working in coordination with hospitals in shared units on the search for tumor markers that can be used in methods of early diagnosis and disease progression, in the design of biosensors for early detection, in obtaining antibodies for therapeutic purposes and in the design and synthesis of new drugs with anti-tumor and antioxidant capacity. As a result of these investigations ther have been obtained several patents, both domestic and international.

Other groups are working in diabetes, thyroid disorders, nutrition and toxicity. It is well known that disorders such as diabetes and obesity are of increasing prevalence and concern, and most current treatments address the symptoms but not the underlying causes of disease. It is important to take coordinated efforts to identify new therapeutic targets and the basis of pathogenesis in order to address the treatment, efficiently.

Another major challenge is to understand the nervous system and its pathologies. The enormous complexity of this neuromuscular and neuronal communication system is addressed ranging from the ionic-molecular study of neuronal excitation by electrophysiological methods, to complex patterns of behavior observed in neurological disorders and psychiatric disorders.

Nanotechnology opens today a promising future in biomedicine, potentially useful in diagnostic techniques (in vivo and in vivo), in the design of new materials (catheters, prosthetic ...), and even in treatment. Meeting together Chemistry-Physics, Medicine, Immunology and Physiology groups, already in research projects (Consolider Ingenio -european-, FIS Project -national-, Xunta de Galicia -regional-) for development bioassay using nanoparticles, or functionalization of nanostructures with antibodies, proteins, DNA, etc., for antitumor therapy, or to ascertain the effect of nanoparticles on the body and its biodistribution.

CHUVI / UVIGO Shared Units. (SERGAS / University)

At the moment, some of our groups lead or participate in these research Shared Units between University and Hospital Complex, such as:

- Genetic basis of diseases of the thyroid gland (GENFERTI)
- Immunology (IMMUNO)
- Translational Bioinformatics (INBIT)
- Biomedical / surgical unit, bioinformatics and analytical proteomics (INBIOPROT)
- Molecular biomarkers in respiratory pathology (BMPR)
- Endocrinology, Clinical Nutrition and Analysis (INVENA)
- Genetics of AIDS (VIHXEN)
- Pharmacoproteomic and Pharmacogenomics (FARMAPROGEN)

Current Funded Projects within INBIOMED.

Many groups in our cluster have already funded projects in biomedicine. Our cluster will empower these collaborations and enable future ones, some examples are:

- PGIDIT06TMT31402PR Xunta de Galicia "Nanoparticles in biological systems. Immune response and diagnosis ", between groups of Immunology and Nanomedicine.
- FIS PI080751 "Biocompatibility and immune response to nanovacunes ", between groups of Immunology and Endocrinology
- CONSOLIDER INGENIO CSD2006-12 "Nanotechnologies for Applications in Biomedicine (NANOBIOMED)", between groups of Immunology and Nanomedicine.